Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Clinical evidence

RINGSIDE part A

95 evidence topics · 9 sources

Objective
Location and study date
Registry dates and study identifier
FieldQuoted record
First posted“2021-05-04”
Study start (actual)“2021-09-01”
Other study ID“AL-DES-01”
Study design
Eligibility criteria
Registry inclusion criteria for Part A

“Inclusion Criteria Part A:” (opens the source at this quote in a new tab)

“At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).” (opens the source at this quote in a new tab)

“Disease progression, assessed locally by the investigator, defined as having at least one of the following:” (opens the source at this quote in a new tab)

“Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI” (opens the source at this quote in a new tab)

“Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication” (opens the source at this quote in a new tab)

“At least 1 measurable lesion amenable to volume measurements by MRI at screening” (opens the source at this quote in a new tab)

“Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR” (opens the source at this quote in a new tab)

“Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)” (opens the source at this quote in a new tab)

“Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment
FieldQuoted record
Enrollment (actual)“198”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics by dose arm
Characteristic1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Age, years, mean (SD)“42.1 (11.32)”“37.8 (14.76)”“39.9 (13.99)”“39.9 (13.23)”
Female, No. (%)“11 (78.6)”“9 (64.3)”“11 (78.6)”“31 (73.8)”
Women of childbearing potential, No. (%)“9 (64.3)”“7 (50.0)”“7 (50.0)”“23 (54.8)”
Intra-abdominal tumor at screening, No. (%)“3 (21.4)”“4 (28.6)”“3 (21.4)”“10 (23.8)”
Tumor volume at baseline by BICR, cm3, mean (SD)“83.93 (92.280)”“189.17 (368.846)”“166.91 (211.038)”“146.05 (242.664)”
CTNNB1 mutation, No. (%)“8 (57.1)”“4 (28.6)”“8 (57.1)”“20 (47.6)”
APC mutation, No. (%)“2 (14.3)”“5 (35.7)”“2 (14.3)”“9 (21.4)”
Prior systemic therapy, No. (%)“9 (64.3)”“13 (92.9)”“7 (50.0)”“29 (69.0)”
Prior surgery, No. (%)“7 (50.0)”“8 (57.1)”“4 (28.6)”“19 (45.2)”
Prior radiation therapy, No. (%)“1 (7.1)”“2 (14.3)”“1 (7.1)”“4 (9.5)”
Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%)“11 (78.6)”“14 (100.0)”“10 (71.4)”“35 (83.3)”
Tumor-related pain not adequately controlled with nonopioid medicine, No. (%)“5 (35.7)”“5 (35.7)”“5 (35.7)”“15 (35.7)”
Median age, performance status, and median baseline tumor volume
Characteristic1.2 mg once daily (n=14)All doses (N=42)
Age (years), median (min, max)“44.0 (24, 61)”“38.5 (19, 72)”
ECOG performance status 0, n (%)“14 (100.0)”“35 (83.3)”
ECOG performance status 1, n (%)“0”“7 (16.7)”
Intra-abdominal tumor at initial diagnosis, n (%)“5 (35.7)”“12 (28.6)”
Extra-abdominal tumor at initial diagnosis, n (%)“9 (64.3)”“30 (71.4)”
Tumor volume at baseline (cm3), median (min, max)“46.30 (1.4, 244.9)”“65.10 (1.4, 1270.3)”
Efficacy results
Tumor response by BICR per RECIST v1.1 during the randomized trial
Response1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Partial response, No. (%)“5 (35.7)”“3 (21.4)”“3 (21.4)”“11 (26.2)”
Stable disease, No. (%)“7 (50.0)”“6 (42.9)”“10 (71.4)”“23 (54.8)”
Progressive disease, No. (%)“0”“2 (14.3)”“0”“2 (4.8)”
Not available, No. (%)“2 (14.3)”“3 (21.4)”“1 (7.1)”“6 (14.3)”
Objective response 95% CI“12.8 to 64.9”“4.7 to 50.8”“4.7 to 50.8”“13.9 to 42.0”
Time to objective response, weeks, median (min, max)“30.00 (17.3, 40.9)”“40.29 (38.3, 41.0)”“51.00 (40.3, 53.7)”“40.29 (17.3, 53.7)”
Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined
ResponseOriginal 1.2 mg once daily (n = 14)Original 2 mg intermittent (n = 14)Original 4 mg intermittent (n = 14)All (N = 42)
Complete response, No. (%)“0”“1 (7.1)”“1 (7.1)”“2 (4.8)”
Partial response, No. (%)“8 (57.1)”“6 (42.9)”“8 (57.1)”“22 (52.4)”
Objective response, No. (%)“8 (57.1)”“7 (50.0)”“9 (64.3)”“24 (57.1)”
Objective response 95% CI“28.9 to 82.3”“23.0 to 77.0”“35.1 to 87.2”“41.0 to 72.3”
Time to objective response, weeks, median (min, max)“37.71 (17.3, 65.1)”“40.57 (28.1, 101.6)”“63.00 (40.3, 121.3)”“51.50 (17.3, 121.3)”
Duration of response, weeks, median (95% CI)“NE (46.1 to NE)”“NE (24.9 to NE)”“NE (NE to NE)”“NE (NE to NE)”
Objective response rate from 43% to 78% across subgroups
SubgroupResponders, No. (%)
Age ≤40 years (n=22) vs. >40 years (n=14)“13 (59) vs. 10 (71)”
Tumor size <70 mm (n=18) vs. ≥70 mm (n=14)“13 (72) vs. 9 (64)”
Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9)“6 (55), 10 (63), 7 (78)”
Intra-abdominal (n=9) vs. extra-abdominal (n=27)“4 (44) vs. 19 (70)”
APC (n=7) vs CTNNB1 (n=19) mutation“3 (43) vs. 13 (68)”
Objective response and duration of response by subgroup as of January 6, 2025
SubgroupORR, n (%)DOR, weeks, median (min, max)
All MRI-evaluable patients (n=37)“24 (65)”“58.9 (12.1, 120.6)”
Age ≤40 years (n=22)“13 (59)”“66.1 (22.1, 110.0)”
Age >40 years (n=15)“11 (73)”“37.1 (12.1, 120.6)”
Tumor size <70 mm (n=19)“10 (53)”“52.1 (22.1, 99.0)”
Tumor size ≥70 mm (n=18)“14 (78)”“78.4 (12.1, 120.6)”
Prior lines of therapy 0 (n=11)“6 (55)”“79.8 (22.1, 95.9)”
Prior lines of therapy 1 (n=13)“9 (69)”“37.1 (12.1, 120.6)”
Prior lines of therapy 2+ (n=13)“9 (69)”“56.0 (12.1, 110.0)”
Intra-abdominal (n=10)“5 (50)”“46.1 (12.1, 99.0)”
Extra-abdominal (n=27)“19 (70)”“61.9 (12.1, 120.6)”
APC mutation (n=8)“4 (50)”“55.4 (12.1, 66.1)”
CTNNB1 mutation (n=19)“13 (68)”“79.6 (22.1, 120.6)”
CTNNB1 S45F (n=3)“2 (67)”“31.0 (24.9, 37.1)”
CTNNB1 T41A (n=5)“2 (40)”“88.2 (55.9, 120.6)”
CTNNB1 other (n=11)“9 (82)”“82.0 (22.1, 110.0)”
Objective response and median best change in tumor volume in the evaluable population
Response1.2 mg QD dose (n=12)All doses (n=36)
Objective response rate (CR + PR), n (%)“9 (75%)”“23 (64%)”
Complete response, n (%)“0 (0%)”“2 (6%)”
Partial response, n (%)“9 (75%)”“21 (58%)”
Stable disease, n (%)“3 (25%)”“12 (33%)”
Progressive disease, n (%)“0 (0%)”“1 (3%)”
Disease control rate, n (%)“12 (100%)”“35 (97%)”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events during the randomized trial by dose arm
Treatment-emergent adverse event, No. (%)1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Any event“14 (100.0)”“14 (100.0)”“14 (100.0)”“42 (100.0)”
Treatment-related“14 (100.0)”“13 (92.9)”“14 (100.0)”“41 (97.6)”
Grade ≥3“5 (35.7)”“7 (50.0)”“4 (28.6)”“16 (38.1)”
Treatment-related grade ≥3“3 (21.4)”“3 (21.4)”“3 (21.4)”“9 (21.4)”
Serious“1 (7.1)”“4 (28.6)”“1 (7.1)”“6 (14.3)”
Leading to dose reduction“6 (42.9)”“0”“5 (35.7)”“11 (26.2)”
Leading to interruption“11 (78.6)”“5 (35.7)”“7 (50.0)”“23 (54.8)”
Leading to study drug withdrawal“4 (28.6)”“2 (14.3)”“0”“6 (14.3)”
Diarrhea“14 (100.0)”“8 (57.1)”“12 (85.7)”“34 (81.0)”
Nausea“7 (50.0)”“4 (28.6)”“10 (71.4)”“21 (50.0)”
Fatigue“7 (50.0)”“5 (35.7)”“6 (42.9)”“18 (42.9)”
Alopecia“7 (50.0)”“2 (14.3)”“4 (28.6)”“13 (31.0)”
Dry skin“7 (50.0)”“1 (7.1)”“5 (35.7)”“13 (31.0)”
Hypophosphatemia“6 (42.9)”“5 (35.7)”“2 (14.3)”“13 (31.0)”
Headache“1 (7.1)”“5 (35.7)”“6 (42.9)”“12 (28.6)”
Stomatitis“7 (50.0)”“2 (14.3)”“3 (21.4)”“12 (28.6)”
Amenorrhea“4 (28.6)”“3 (21.4)”“4 (28.6)”“11 (26.2)”
AST increased“4 (28.6)”“4 (28.6)”“3 (21.4)”“11 (26.2)”
Hot flush“3 (21.4)”“4 (28.6)”“4 (28.6)”“11 (26.2)”
Vomiting“3 (21.4)”“4 (28.6)”“4 (28.6)”“11 (26.2)”
Adverse events of special interest by dose arm, appendix table
Event, No. (%)1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
One or more adverse events of special interest“6 (42.9)”“5 (35.7)”“5 (35.7)”“16 (38.1)”
Amenorrhea“3 (21.4)”“3 (21.4)”“4 (28.6)”“10 (23.8)”
Premature menopause“0”“0”“1 (7.1)”“1 (2.4)”
Elevated liver enzymes (CTCAE grade ≥2)“2 (14.3)”“2 (14.3)”“0”“4 (9.5)”
Squamous cell carcinoma of skin“1 (7.1)”“0”“0”“1 (2.4)”
Treatment-emergent adverse events in the randomized trial and open-label extension combined
Treatment-emergent adverse event, No. (%)Original 1.2 mg once daily (n = 14)Original 2 mg intermittent (n = 14)Original 4 mg intermittent (n = 14)All doses (N = 42)
Grade ≥3“6 (42.9)”“11 (78.6)”“6 (42.9)”“23 (54.8)”
Treatment-related grade ≥3“4 (28.6)”“6 (42.9)”“4 (28.6)”“14 (33.3)”
Serious“1 (7.1)”“6 (42.9)”“1 (7.1)”“8 (19.0)”
Leading to dose reduction“7 (50.0)”“3 (21.4)”“8 (57.1)”“18 (42.9)”
Leading to interruption“11 (78.6)”“8 (57.1)”“9 (64.3)”“28 (66.7)”
Leading to study drug withdrawal“4 (28.6)”“4 (28.6)”“1 (7.1)”“9 (21.4)”
Diarrhea“14 (100.0)”“9 (64.3)”“12 (85.7)”“35 (83.3)”
Nausea“8 (57.1)”“5 (35.7)”“10 (71.4)”“23 (54.8)”
Fatigue“8 (57.1)”“6 (42.9)”“8 (57.1)”“22 (52.4)”
Hypophosphatemia“7 (50.0)”“5 (35.7)”“3 (21.4)”“15 (35.7)”
Stomatitis“7 (50.0)”“5 (35.7)”“3 (21.4)”“15 (35.7)”
Cough“3 (21.4)”“5 (35.7)”“6 (42.9)”“14 (33.3)”
Rash“1 (7.1)”“7 (50.0)”“6 (42.9)”“14 (33.3)”
Upper respiratory tract infection“3 (21.4)”“2 (14.3)”“6 (42.9)”“11 (26.2)”
Study limitations
Summary
  • RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
  • The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
  • The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
  • Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
  • Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
  • Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.